Ajooni Biotech Limited has informed the Exchange regarding Board meeting held on August 14, 2025.
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajooni Biotech's Board met on August 14, 2025 and approved the unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26). Revenue from operations rose to ₹3,126.77 lakhs from ₹2,565.85 lakhs in Q1 FY25, a year-on-year growth of about 22%. Net profit for the quarter climbed to ₹78.14 lakhs from ₹46.82 lakhs, up roughly 67% year-on-year. Basic EPS stood at ₹0.02 versus ₹0.03 in the same quarter last year. On the balance sheet, total assets grew to ₹9,992.52 lakhs as of June 30, 2025, with cash and cash equivalents more than doubling to ₹1,574.89 lakhs. The auditor (Narinder Kumar and Company) issued an unqualified limited review report on the results.
Strong top-line growth and a sharp jump in net profit signal improving operating performance, which is positive for shareholders. However, EPS remained flat to slightly lower despite higher profits, likely because the share base has expanded. The re-appointment of Mr. Gursimran Singh as Whole Time Director for five years provides continuity in leadership.